Fosinopril Sodium/Hydrochlorothiazide

福辛普利钠/氢氯噻嗪

Report date: 2022/01/14 13:23:58

Base Information

Drug NameFosinopril Sodium/Hydrochlorothiazide
Drug Alias Name氢氯噻嗪/福辛普利钠Hydrochlorothiazide/Fosinopril SodiumHydrochlorothiazide and Fosinopril SodiumFosinopril Sodium and HydrochlorothiazideMonopril-HCT
ClassificationSmall molecules
Mechanisms of ActionThiazide-sensitive sodium-chloride cotransporter inhibitorsAngiotensin-converting enzyme inhibitors
TargetsThiazide-sensitive sodium-chloride cotransporterAngiotensin-converting enzyme
Therapy Area/IndicationsHypertension
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1994/11/30
Country/TerritoryUnited States
CombinationsYes HydrochlorothiazideFosinopril Sodium
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsHypertension

Other Information

ATC CodeC09BA09
Related LinksKEGG